Plain-English translation of NCT06498479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called can help people with small cell lung cancer that has returned or progressed after their first round of chemotherapy. Half the participants will receive , and half will receive , a standard treatment option. The trial will track how long people survive to see if the new medication works better than the current standard.
Small cell lung cancer often comes back after initial chemotherapy, and doctors need better treatment options for patients at this stage. This medication is being tested to see if it can help people live longer and have better outcomes than the current standard treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either or as an intravenous infusion every 21 days. You will continue treatment until your cancer progresses or you experience unmanageable side effects. Throughout the trial, you will have regular hospital visits for infusions, blood tests, imaging scans to measure your tumor, and check-ins with your doctor to monitor how you're responding and managing any side effects. The study will enroll about 460 people across multiple cancer centers.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China